Instil Bio (TIL) Cash from Restructuring (2022 - 2024)

Instil Bio has reported Cash from Restructuring for 3 years, with the latest figure at -$853000.0 in Q2 2024.

• On a quarterly basis, Cash from Restructuring rose 48.98% year-over-year to -$853000.0 in Q2 2024; TTM through Jun 2024 was -$494000.0, a N/A change from a year earlier, with the FY2023 full-year figure at -$2.3 million, down 142.29% from the prior year.
• Cash from Restructuring was -$853000.0 for Q2 2024 at Instil Bio, down from $778000.0 in the prior quarter.
• The five-year high for Cash from Restructuring was $5.4 million in Q4 2022, with the low at -$1.7 million in Q2 2023.
• Average Cash from Restructuring over 3 years is $437285.7, with a median of -$207000.0 recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Cash from Restructuring slumped 100.96% in 2023, then jumped 475.85% in 2024.
• Over 3 years, Cash from Restructuring stood at $5.4 million in 2022, then plunged by 100.96% to -$52000.0 in 2023, then sank by 1540.38% to -$853000.0 in 2024.
• The last three Cash from Restructuring figures came in at -$853000.0 (Q2 2024), $778000.0 (Q1 2024), and -$52000.0 (Q4 2023), per Business Quant data.